ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue-7.25278.9810.012
Cost of Revenue----
Gross Profit-7.25278.9810.012
Operating Expenses
Research Development22,806.10716,784.6267,445.6692,401.406
Selling General and Administrative10,016.9026,430.2525,364.394,076.339
Non Recurring----
Others----
Total Operating Expenses32,823.00923,214.87812,810.0596,477.745
Operating Income or Loss-32,823.009-23,207.628-12,531.159-5,667.733
Income from Continuing Operations
Total Other Income/Expenses Net810.705-208.4227.352-1.844
Earnings Before Interest and Taxes-32,823.009-23,207.628-12,531.159-5,667.733
Interest Expense----1.844
Income Before Tax-32,012.304-23,416.05-12,523.807-5,669.577
Income Tax Expense--27.54327.543-
Minority Interest----
Net Income From Continuing Ops-32,012.304-23,388.507-12,551.35-5,669.577
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-32,012.304-23,388.507-12,551.35-5,669.577
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-32,012.304-23,388.507-12,551.35-5,757.531